Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com
Catalog No. ABIN2854814
  • Target See all Vimentin (VIM) Antibodies
    Vimentin (VIM)
    Reactivity
    • 332
    • 126
    • 125
    • 61
    • 58
    • 43
    • 42
    • 36
    • 29
    • 21
    • 20
    • 13
    • 13
    • 8
    • 7
    • 6
    • 6
    • 4
    • 3
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Human
    Host
    • 189
    • 129
    • 9
    • 6
    • 4
    • 4
    • 2
    Rabbit
    Clonality
    • 197
    • 145
    Polyclonal
    Conjugate
    • 199
    • 19
    • 13
    • 13
    • 11
    • 7
    • 7
    • 7
    • 7
    • 7
    • 7
    • 7
    • 4
    • 4
    • 4
    • 4
    • 4
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    This Vimentin antibody is un-conjugated
    Application
    • 281
    • 132
    • 98
    • 97
    • 95
    • 64
    • 48
    • 40
    • 39
    • 27
    • 23
    • 19
    • 8
    • 5
    • 4
    • 4
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    Western Blotting (WB), Immunohistochemistry (IHC), ELISA, Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunocytochemistry (ICC), Immunoprecipitation (IP), Immunohistochemistry (Frozen Sections) (IHC (fro))
    Cross-Reactivity
    Cat, Dog, Human, Mouse, Rat
    Characteristics
    Rabbit Polyclonal antibody to Vimentin (vimentin)
    Vimentin antibody
    Purification
    Purified by antigen-affinity chromatography.
    Grade
    KO Validated
    Immunogen
    Recombinant protein encompassing a sequence within the center region of human Vimentin. The exact sequence is proprietary.
    Isotype
    IgG
    Top Product
    Discover our top product VIM Primary Antibody
  • Application Notes
    WB: 1:5000-1:50000. ICC/IF: 1:100-1:1000. IHC-P: 1:100-1:1000. IP: 1:100-1:500. Optimal dilutions/concentrations should be determined by the researcher. Not tested in other applications.
    Comment

    Positive Control: 293T

    Validation: Comparison, KO/KD, Orthogonal, Overexpression

    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    0.11 mg/mL
    Buffer
    1XPBS ( pH 7), 1 % BSA, 20 % Glycerol, 0.025 % ProClin 300
    Preservative
    ProClin
    Precaution of Use
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Storage
    4 °C,-20 °C
    Storage Comment
    Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4°C. For long-term storage, aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles.
  • Navarrete-Bernal, Cervantes-Badillo, Martínez-Herrera, Lara-Torres, Gerson-Cwilich, Zentella-Dehesa, Ibarra-Sánchez, Esparza-López, Montesinos, Cortés-Morales, Osorio-Pérez, Villegas-Osorno et al.: "Biological Landscape of Triple Negative Breast Cancers Expressing CTLA-4. ..." in: Frontiers in oncology, Vol. 10, pp. 1206, (2020) (PubMed).

    Klein, Lohr, Droste: "Age-Dependent Heterogeneity of Murine Olfactory Bulb Astrocytes." in: Frontiers in aging neuroscience, Vol. 12, pp. 172, (2020) (PubMed).

    Horn, Riskin, Hempel, Fousek, Lind, Hamilton, McCampbell, Maeda, Zebala, Su, Schlom, Palena: "Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity." in: Journal for immunotherapy of cancer, Vol. 8, Issue 1, (2020) (PubMed).

    Wang, Liu, Jeng, Chiang, Chai, Chiou, Huang, Yokoyama, Wang, Huang, Hsu: "PCAF-mediated acetylation of ISX recruits BRD4 to promote epithelial-mesenchymal transition." in: EMBO reports, Vol. 21, Issue 2, pp. e48795, (2020) (PubMed).

    Diao, Ge, Song, Wu, Li, Li, Yang, Wang, Cheng: "Overexpression of ZEB2-AS1 promotes epithelial-to-mesenchymal transition and metastasis by stabilizing ZEB2 mRNA in head neck squamous cell carcinoma." in: Journal of cellular and molecular medicine, Vol. 23, Issue 6, pp. 4269-4280, (2020) (PubMed).

    Xie, Zhao, Guo, Liu, Fu, Fan, Lin, Chen, Wang, Fan, Wei: "Benzyl isothiocyanate suppresses development and metastasis of murine mammary carcinoma by regulating the Wnt/β‑catenin pathway." in: Molecular medicine reports, Vol. 20, Issue 2, pp. 1808-1818, (2019) (PubMed).

    Offer, Menard, Pérez, de Oliveira, Chandran, Johansson, Bång-Rudenstam, Siesjö, Ebbesson, Hedenfalk, Sundgren, Darabi, Belting: "Extracellular lipid loading augments hypoxic paracrine signaling and promotes glioma angiogenesis and macrophage infiltration." in: Journal of experimental & clinical cancer research : CR, Vol. 38, Issue 1, pp. 241, (2019) (PubMed).

    Hua, Liu, Hsu, Cheng, Yang, Chang, Lee, Hsiao, Juan, Chien, Yang: "3'UTR polymorphisms of carbonic anhydrase IX determine the miR-34a targeting efficiency and prognosis of hepatocellular carcinoma." in: Scientific reports, Vol. 7, Issue 1, pp. 4466, (2019) (PubMed).

    Chu, Lee, Lee, Wang, Huang, Lan, Lin, Lin, Tian, Liu, Chow: "MiR-338-5p promotes metastasis of colorectal cancer by inhibition of phosphatidylinositol 3-kinase, catalytic subunit type 3-mediated autophagy pathway." in: EBioMedicine, Vol. 43, pp. 270-281, (2019) (PubMed).

    Nakazawa, Taniyama, Sanada, Morishita, Nakamori, Morimoto, Yeung, Yang: "Periostin blockade overcomes chemoresistance via restricting the expansion of mesenchymal tumor subpopulations in breast cancer." in: Scientific reports, Vol. 8, Issue 1, pp. 4013, (2019) (PubMed).

    Chiu, Wen, Wang, Hsu, Tsai, Hung, Tseng, Shyr: "Role of estrogen receptors and Src signaling in mechanisms of bone metastasis by estrogen receptor positive breast cancers." in: Journal of translational medicine, Vol. 15, Issue 1, pp. 97, (2018) (PubMed).

    Wang, Wu, Yeh, Su, Hsia, Liang, Chen, Hsueh, Chen: "Melatonin suppresses hepatocellular carcinoma progression via lncRNA-CPS1-IT-mediated HIF-1α inactivation." in: Oncotarget, Vol. 8, Issue 47, pp. 82280-82293, (2017) (PubMed).

    Hsu, Chang, Hsu, Liu, Yeh, Wang, Liou, Ko, Chang, Chuang: "Suberoylanilide hydroxamic acid represses glioma stem-like cells." in: Journal of biomedical science, Vol. 23, Issue 1, pp. 81, (2017) (PubMed).

    Yin, Yin, Wang, Zhou, Liu, Yang, Wang, Lu: "MiR-206 suppresses epithelial mesenchymal transition by targeting TGF-β signaling in estrogen receptor positive breast cancer cells." in: Oncotarget, Vol. 7, Issue 17, pp. 24537-48, (2017) (PubMed).

    Marquez-Vilendrer, Rai, Gramling, Lu, Reisman: "Loss of the SWI/SNF ATPase subunits BRM and BRG1 drives lung cancer development." in: Oncoscience, Vol. 3, Issue 11-12, pp. 322-336, (2016) (PubMed).

    Hou, You, Yang, Pan, Chen, Lee, Lin, Liou, Liu, Chi, Ger, Tsai: "Aberrant DNA hypomethylation of miR-196b contributes to migration and invasion of oral cancer." in: Oncology letters, Vol. 11, Issue 6, pp. 4013-4021, (2016) (PubMed).

    Wei, Nickoloff, Chen, Liu, Lo, Chang, Yang, Wu, Williams, Gelovani, Deng: "FOXF1 mediates mesenchymal stem cell fusion-induced reprogramming of lung cancer cells." in: Oncotarget, Vol. 5, Issue 19, pp. 9514-29, (2015) (PubMed).

  • Target
    Vimentin (VIM)
    Alternative Name
    vimentin (VIM Products)
    Synonyms
    CTRCT30 antibody, cb28 antibody, vime antibody, vim antibody, vim1 antibody, vim2 antibody, VIM antibody, Vimentin antibody, vim4 antibody, vimentin antibody, vimentin L homeolog antibody, vimentin S homeolog antibody, VIM antibody, Vim antibody, vim antibody, vim.L antibody, vim.S antibody
    Background
    Along with the microfilaments (actins) and microtubules (tubulins), the intermediate filaments represent a third class of well-characterized cytoskeletal elements. The subunits display a tissue-specific pattern of expression. Desmin (MIM 125660) is the subunit specific for muscle and vimentin the subunit specific for mesenchymal tissue.[supplied by OMIM]

    Molecular Weight
    54 kDa
    Gene ID
    7431
    UniProt
    P08670
    Pathways
    Caspase Cascade in Apoptosis
You are here:
Support